Author

F. Canale

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Assay:flow cytometry· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

A. Combes· 1 shared A. del Castillo· 1 shared A. Gruppi· 1 shared A. Salomon· 1 shared B. Samad· 1 shared C. Abrate· 1 shared C. L. Montes· 1 shared C. Rodriguez· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Combes

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

CD39+ conventional CD4+ T cells with exhaustion traits and cytotoxic potential infiltrate tumors and expand upon CTLA-4 blockade

S. N. Bossio, C. Abrate, J. Tosello Boari, C. Rodriguez, F. Canale, M. C. Ramello, W. Richer, D. Rocha, C. Sedlik, A. Salomon, E. Borcoman, A. del Castillo, A. Gruppi, E. Fernandez, E. V. Acosta Rodriguez, C. L. Montes

The paper identifies CD39+ CD4+ T cells in tumors with exhaustion and cytotoxic traits, showing their expansion with CTLA-4 blockade and association with better survival in breast cancer.

bioRxiv · Jan 30, 2023Immunology

Myeloid mechano-metabolic programming restricts anti-tumor immunity

K. Tharp, K. Kersten, O. Maller, G. Timblin, C. Stashko, F. Canale, M.-K. Hayward, I. Berestjuk, J. ten Hoeve-Scott, B. Samad, R. Geiger, A. Combes, V. Weaver

This study shows that fibrotic tumor microenvironments impair anti-tumor immunity through myeloid cell-driven metabolic changes that hinder CD8+ T cell function.

bioRxiv · Jul 14, 2022 · PreprintCancer Biology